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AbstrAct
Introduction Recent avoidable failures in patient 
care highlight the ongoing need for evidence to 
support improvements in patient safety. According 
to the most recent reviews, there is a dearth of 
economic evidence related to patient safety. These 
reviews characterise an evidence gap in terms 
of the scope and quality of evidence available to 
support resource allocation decisions. This protocol 
is designed to update and improve on the reviews 
previously conducted to determine the extent of 
methodological progress in economic analyses in 
patient safety.
Methods and analysis A broad search strategy 
with two core themes for original research 
(excluding opinion pieces and systematic reviews) 
in ‘patient safety’ and ‘economic analyses’ has been 
developed. Medline, Econlit and National Health 
Service Economic Evaluation Database bibliographic 
databases will be searched from January 2007 using 
a combination of medical subject headings terms 
and research-derived search terms (see table 1). The 
method is informed by previous reviews on this topic, 
published in 2012. Screening, risk of bias assessment 
(using the Cochrane collaboration tool) and economic 
evaluation quality assessment (using the Drummond 
checklist) will be conducted by two independent 
reviewers, with arbitration by a third reviewer as 
needed. Studies with a low risk of bias will be 
assessed using the Drummond checklist. High-quality 
economic evaluations are those that score >20/35. 
A qualitative synthesis of evidence will be performed 
using a data collection tool to capture the study 
design(s) employed, population(s), setting(s), disease 
area(s), intervention(s) and outcome(s) studied. 
Methodological quality scores will be compared with 
previous reviews where possible. Effect size(s) and 
estimate uncertainty will be captured and used in a 
quantitative synthesis of high-quality evidence, where 
possible.
Ethics and dissemination Formal ethical approval is 
not required as primary data will not be collected. The 
results will be disseminated through a peer-reviewed 
publication, presentations and social media.
trial registration number CRD42017057853.
IntroductIon
After recent focusing events in which avoid-
able failures in healthcare were identified, 
patient safety remains high on the clinical 
and policy agenda in health systems. The 
burden of lapses in safety is high in devel-
oped health systems. In the USA, the Office 
of the Inspector General (OIG) estimated an 
adverse event (AE) rate of 13.5% for hospi-
talised Medicare beneficiaries, amounting to 
approximately 180 000 additional deaths per 
annum.1 For the UK, the rate is estimated to 
be 10.8%, although there are limitations to 
this calculation and the methodology differs 
to that used by the US OIG.2 3 According 
to the most recent systematic reviews of 
economic analyses in patient safety, there 
is a dearth of high-quality evidence on the 
economic impact of avoidable harm and the 
interventions that aim to improve safety. As 
such, there is limited evidence to support 
resource allocation decisions in this area. 
Meltzer summarised the state of evidence 
in a 2012 editorial in which economic 
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Protocol
strengths and limitations of this study
 ► A strength of the proposed study is the application of 
transparent and replicable procedures for searching 
health economic literature.
 ► The breadth of the search strategy is a strength as 
it lends to generating findings that are translational.
 ► A weakness of this study is the close but imperfect 
replication of previous reviews. This limits the 
comparability of this study’s findings with others’, 
which also limits our interpretation of the maturation 
of evidence.
 ► Considering previous findings, a large sample 
size for statistical pooling of effect size(s) within 
subgroups is not anticipated. This may limit the 
strength of this protocol as a means of producing a 
quantitative synthesis.
 o
n
 18 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017089 on 18 August 2017. Downloaded from 
2 Carter AW, et al. BMJ Open 2017;7:e017089. doi:10.1136/bmjopen-2017-017089
Open Access 
evaluation in patient safety was described as a ‘neglected 
necessity’.4
In light of findings by Etchells et al5 and De Rezende et 
al,6 there is a need to conduct a new review of economic 
evaluations to measure recent progress in this area. A 
central question is whether the research community has 
produced more high-quality evidence since these publi-
cations. Implicitly, this question should be approached by 
(1) conducting a before and after comparison of studies 
using the same, valid quality assessment instrument and 
(2) this is a prerequisite for a potential metasynthesis of 
recent (last 10 years) evidence.
Etchells et al5 restricted their search to comparative 
evaluations of 15 patient safety target conditions and 6 
improvement strategies using a Medline and Agency for 
Healthcare Research & Quality (AHRQ) Patient Safety 
Network search between 2000 and 2011. Studies that did 
not analyse an intervention with a patient safety target 
or were not in the acute setting were excluded. Studies 
were also excluded if evidence of effectiveness was poor, 
according to the Cochrane collaboration risk of bias 
tool,7 or not cited. Those studies that were included 
were quality assessed using the Drummond checklist,8 
which was completed for each study by two independent 
reviewers. Consensus was achieved based on a five-point 
discrepancy between assessments scores. The findings 
from this review show the paucity of high-quality compar-
ative research.
From this review, only five studies were considered 
high quality: pharmacist-led medication reconciliation 
dominated a strategy of no reconciliation9; additional 
erythropoietin to reduce transfusion-related AEs were 
evaluated against the standard of care in another study10; 
use of chlorohexidine gluconate to reduce catheter-re-
lated infections was found to dominate povidone-iodine 
use11; the Keystone intensive care unit patient safety 
programme was evaluated using effectiveness data 
related to the reduction in central line-associated blood-
stream infections and was found to dominate standard 
of care12; lastly, strategies to reduce retained surgical 
foreign bodies were compared and standard counting 
was found most likely to dominate a no counting 
strategy.13
De Rezende et al6 used Medline, National Health 
Service (NHS) Economic Evaluation Database (EED), 
and Econlit databases to search for English and French 
language economic evaluations from 2000 to 2010. Their 
focus was on characterising the types of AEs studied and 
methods used to estimate costs and cost-effectiveness. Two 
independent reviewers used a common template to assess 
AE type, evaluation method, perspective, population 
studied, cost components, data sources, cost calculation 
methods, outcome measures and results obtained. As 
such, burden studies, cost-effectiveness studies and inter-
vention cost analyses were identified. A quality assessment 
tool was conceived and used to determine studies’ meth-
odological quality and discrepancies were discussed by 
the four authors.
Using a qualitative synthesis, this review found that 
most studies considered healthcare-associated infections 
and/or infection control activities and medication-re-
lated AEs. Three economic burden/cost of-illness studies, 
five complete economic evaluations and two interven-
tion cost studies were described in detail by the research 
group because they were considered high quality (a 
published instrument was not applied for quality assess-
ment). Economic evaluations of hospital deep cleaning 
programmes, staff vaccination against nosocomial 
pertussis, three medication-related AE reduction strat-
egies, a national methicillin-resistant Staphylococcus 
aureus (MRSA) reduction policy and the introduction of 
electronic medical records to reduce prescription errors 
were identified. The findings from this review provide 
insight on the scope of economic analyses performed in 
this area.
Taken together, Etchells et al5 and De Rezende et 
al6characterise the literature from 2000 to 2011 with a 
combination of scope and quality appraisal. There is a 
renewed evidence gap in economic evaluations of patient 
safety for three reasons: (1) the reviews by these research 
groups are no longer recent; (2) the breadth of safety prior-
ities and interventions and the depth of objective quality 
assessment in these reviews have historical and scientific 
limitations and (3) considerable resources continue to be 
invested in patient safety without a renewed synthesis of 
evidence to inform decision-making.
The proposed review will address these three concerns 
by expanding the scope of the review conducted by Etch-
ells et al5 and raising the scientific rigour compared with 
the De Rezende et al6 review. This approach will be essen-
tial to determine the extent to which methodological 
progress has been made since Meltzer’s (2012)4 editorial. 
To ensure that the quality assessment is valid and reliable, 
high-quality studies published after 2007 that were also 
identified in previous reviews will be included for quality 
assessment in this study.
research aims and objectives
This study aims to (1) assess methodological progress 
in economic studies in patient safety and (2) provide a 
quantitative summary and synthesis of the most recent 
evidence in this area.
1. Characterise and describe the types of economic 
analyses performed in patient safety since 2011;
2. Assess the quality of empirical (descriptive and 
comparative/experimental) economic analyses in 
patient safety;
3. Compare the scope and quality of economic evidence 
in patient safety between 2007 and 2011 to the end 
date of the literature search.
Methods and analysis
The scope of this study is driven by the combined aspects 
of the Etchells et al5 and De Rezende et al6 studies. The 
approach is derived using resources that enhance meth-
odological transparency and improve the systematic 
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Table 1 Search themes (facets) and terms derived for each theme relating to economic analyses in patient safety
Patient safety Economic analyses
1. patient harm/or patient safety/or safety management/
or accidental falls/or accident prevention/or infection control/
or antisepsis/or asepsis/or blood safety/or sterilisation/
or disinfection/or sanitation/or decontamination/
or medical errors/or diagnostic errors/or medication errors/
or inappropriate prescribing/or medication reconciliation/
or near miss, healthcare/or Venous Thromboembolism/
or Pulmonary Embolism/or Pressure Ulcer/
2. (nosocomial or Patient safety or iatrogenic or ((Adverse 
or sentinel) adj (outcome* or event* or drug event*)) or 
Incident*one or Error*one or (Near adj miss*2) or Close 
call* or (Never adj event*) or complicat* or (Mis diagnos* 
or misdiagnos*) or (missed adj diagnosis) or (Patient adj 
accident*1) or (((Inappropriate*two or unsafe or wrong) 
adj (transfer or discharge*)) or treatment) or ((Healthcare 
or healthcare) adj (acquired or associated) adj infection*1) 
or ((Wound or Surgical site) adj infection*) or (Fail* adj2 
discontinu*five adj treatment*) or Infusion injur* or ((Missing 
or retained) adj (needle* or swab or instrument or sponge)) 
or Unplanned return to theatre or ((Maternal or mother) 
adj (death* or mortality or readmission)) or Venous 
thromboembolism* or Pulmonary embolism* or Pressure 
ulcer*one or ((wrong adj site surgery) or impact or prosthesis 
or (route adj1 administration adj2 medic*)) or (ABO-
incompatible adj (blood or organ*))).ti,ab.
3. 1 or 2
1. costs and cost analysis/or cost allocation/or cost-benefit 
analysis/or cost of illness/or health care costs/or health 
expenditures/or economics, hospital/or hospital charges/
or hospital costs/or economics, medical/or fees, medical/
2. ((economic burden) adj2 (disease* or illness*)).ti,ab. OR 
(cost* adj2 illness*).ti,ab. OR (cost*3).ti,ab. OR ((healthcare 
or healthcare) adj2 (cost*3)).ti,ab. OR ((cost) adj (analy*three 
or evaluation)).ti,ab. OR (health resource utili#ation).ti,ab. 
OR (cost adj1 effective*).ti,ab. OR (cost adj1 benefit*).ti,ab. 
OR (cost adj utilit*).ti,ab. OR ((economic) adj (evaluation* 
or analysis or burden or impact)).ti,ab. OR (compar*five adj 
econom* adj analys*2).ti,ab. OR (incremental adj analysis).
ti,ab. OR (net adj1 benefit*).ti,ab. OR ((financ*3) adj 
(analy*three or evaluation or manag*5)).ti,ab.
3. (health econom*).ti,ab. OR (value adj2 money).ti,ab. OR 
(expenditure*).ti,ab. OR (financ*).ti,ab. OR (fiscal).ti,ab. 
OR (funding).ti,ab. OR (pharmacoeconomic*).ti,ab. OR 
(socioeconomic*).ti,ab. OR (pric*3).ti,ab. OR (fee*).ti,ab. 
OR (health priorit*).ti,ab. OR (resource allocation).ti,ab. 
OR (economic* adj aspect).ti,ab. OR (efficien*2).ti,ab. OR 
(technical efficien*2).ti,ab. OR (allocative efficien*2).ti,ab. 
OR (productivit*3).ti,ab. OR (organi?ational adj efficien*2).
ti,ab. OR (economic adj endpoint).ti,ab. OR (budget*).ti,ab.
4. 1 or 2 or 3
nature of the search strategy and evidence synthesis. 
These resources are described for both the economic 
and medical aspects of this review. Medline, Econlit and 
NHS EED bibliographic databases will be searched from 
January 2007 using a combination of medical subject 
headings (MeSH) terms and research-derived search 
terms. This approach is considered efficient for searching 
health economic literature.14 The primary outcomes of 
interest in this review are economic endpoints in patient 
safety research.
The overarching approach to this study is summarised in 
the prospective Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) (see online supple-
mentary 1). A completed PRISMA Protocols checklist 
can be found in online supplementary 2. The following 
research stages will be followed:
Search
1. Title and abstract searches using MeSH and researcher-
derived search terms (provided in table 1);
2. Combine database searches, deduplication using a 
prespecified procedure.
Screening
1. Title and abstract screening using prespecified 
inclusion and exclusion criteria;
2. Full-text and reference list screening according to 
pre-specified inclusion and exclusion criteria.
Quality assessment
1. Risk of bias assessment and Drummond checklist 
assessment of economic evaluation quality;
2. Data extraction in accordance with research objectives.
Data synthesis
1. Evidence synthesis of scope and quality of evidence;
2. Presentation and publication of findings;
3. Assessment of evidence for use in subgroup meta-
analyses.
Eligibility criteria
The systematic review does not focus on a particular 
population, disease area or health system setting as it 
intends to characterise the scope of all economic eval-
uations in patient safety. The search criteria are shaped 
around two core themes for original research in ‘patient 
safety’ and ‘economic analyses’. We define patient safety 
as ‘The avoidance, prevention and amelioration of 
adverse outcomes or injuries stemming from the process 
of healthcare’.15 Economic analyses in this study broadly 
refer to cost-of-illness, cost-effectiveness, cost utility, 
cost benefit, cost consequence, cost minimisation and 
cost analysis studies.
Search terms will be restricted to title and abstract 
only at the screening stage. The time frame for study 
selection is decided by the completion dates of previous 
reviews,therefore all studies published since January 
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2007. This also allows for overlap between the current 
study and previous reviews, ensuring appropriate articles 
are included.
Inclusion criteria
 ► Participants/population: individuals of any age and 
gender, all index admissions and in all health system 
settings who are at risk of experiencing a safety-relat-
ed AEs;
 ► Intervention(s): this review is deliberately broad and 
is designed to include descriptive and intervention 
studies. Interventions refer to any care process that 
intends to reduce the incidence of safety-related AEs. 
These may include new drugs (or drug-presentations), 
procedures, guidelines and policies that are produced 
to improve patient safety;
 ► Comparators: all comparison groups;
 ► Outcomes: all economic and clinical outcomes relat-
ed to patient safety will be considered.
Exclusion criteria
 ► Participants/population: articles that report popula-
tions not at risk of iatrogenic harm;
 ► Intervention(s): any studies reporting on non-safe-
ty-related interventions that is, those that do not ex-
plicitly intend to reduce the rates of harm;
 ► Comparators: no specific exclusion;
 ► Outcomes: studies with outcomes that are not consid-
ered a consequence of patient safety interventions will 
be disregarded;
 ► Timing: studies published during or before Decem-
ber 2006;
 ► Studies that do not report economic data.
Other general exclusion criteria
 ► Non-English language articles;
 ► Opinion: letters, editorials and commentaries;
 ► Systematic reviews and book chapters;
 ► Partial or non-peer reviewed evidence: conference ab-
stracts, study protocols.
The review will consider both experimental and epide-
miological study designs that are incorporated with 
economic analyses. We will therefore include randomised 
controlled trials, non-randomised controlled trials, 
quasi-experimental before and after studies, prospective 
and retrospective cohort studies, case–control studies 
and analytical cross-sectional studies. Only peer-reviewed 
publications of original research will be considered, and 
these criteria are satisfied by applying the Neyt and Chalon 
optimised procedure for searching economic evaluations 
in Medline.16 This procedure may be used exclusively or 
in combination with the research group’s search terms.
screening
Initial search result titles, abstracts and index or keyword 
terms will be screened. Studies will be screened by two 
reviewers acting independently. Reference lists of all 
identified reports and articles will be searched for other 
relevant studies.
After title and abstract screening, full-text reviews will 
be conducted.
Exclusion criterion
 ► Studies that do not investigate economic outcomes;
 ► Studies that do not investigate patient safety.
The two reviewers will extract relevant data on study 
design, funding, population(s), setting(s), disease 
area(s), intervention(s), outcome(s) and effect size(s). 
These data will be used to for the quality assessment of 
the review.
Quality assessment
Two reviewers will independently assess the risk of bias 
in studies using the Cochrane collaboration risk of bias 
tool.7 This tool will be applied to assess the quality of 
effectiveness data reported and used for cost-effectiveness 
analyses. It will also be used to assess epidemiological and 
observational findings. Overall, the quality assessment 
will consider the following study-level aspects:
 ► Randomisation sequence generation: was the alloca-
tion sequence generated appropriately?
 ► Treatment allocation concealment: were study par-
ticipants, clinicians and other healthcare or research 
staff unaware of the intervention(s) given at the en-
rolment stage?
 ► Blinding: were the personnel assessing outcomes and 
analysing data blinded to the intervention allocated 
during the trial?
 ► Completeness of outcome data: were participant ex-
clusions, attrition and incomplete outcome data ade-
quately reported in the published manuscript?
 ► Selective outcome reporting: is there evidence of se-
lective outcome reporting and could this have biased 
the study results?
 ► Other sources of bias: was the study apparently free of 
any other high-risk sources of bias?
Disagreements between the review authors over the risk 
of bias studies will be resolved by discussion, with arbi-
tration by a third reviewer where necessary. For studies 
considered to have a low risk of bias and that also report 
economic evidence, the Drummond checklist for assessing 
the methodology quality of economic evaluations will be 
applied. Two independent reviewers will score these (out 
of 35). Scores will be reviewed by a second reviewer and 
any disagreements in score of >5 will be resolved with arbi-
tration by a third reviewer.
data synthesis
A descriptive (qualitative) analysis of the scope of 
economic evidence in patient safety will be presented. 
Consistent with De Rezende et al,6 the types of economic 
analyses will be presented as studies of either economic 
burden/cost of illness or cost analysis of interventions or 
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full economic evaluations (encompassing cost and effec-
tiveness data).
The populations (by demographic), settings (primary, 
secondary, community or social care), diseases areas 
(problems of circulation, cancers and tumours, mental 
disorders, musculoskeletal system and connective tissue) 
and interventions (safety-related AE that is targeted—
either infection-related, medication AE, surgical safety, 
hospital accidents) of all economic analyses will be 
presented.
A synthesis of quality scores for risk of bias and economic 
evaluation quality will be given. Effect size(s) and cost-ef-
fectiveness results of high-quality papers—those scoring 
above 20 on the Drummond checklist—will be reported. 
This cut-off score is consistent with that used by Etch-
ells et al.5 Sensitivity analysis results will also be given, if 
reported. The sensitivity of review findings to stratifica-
tion of evidence quality will also be explored.
A quantitative synthesis will be performed if necessary 
data are available. High-quality findings from compara-
tive analyses will be compared with findings from Etchells 
et al5 and De Rezende et al’s6 reviews. High-quality findings 
identified in these reviews and that were published after 
2006 will be included for quantitative synthesis. Effective-
ness estimates will be grouped by the type of safety-related 
AE that are the target of interventions identified in the 
review (for example, nosocomial infections). Estimates 
will then be pooled for statistical meta-analysis. Hetero-
geneity will be assessed statistically using an appropriate 
test statistic (such as χ2). Effect sizes expressed as OR (for 
categorical data) and weighted mean differences (for 
continuous data) and their 95% CIs will be calculated for 
analysis. Where statistical pooling is not possible, findings 
will be tabulated for comparison.
Metabiases will be determined using the risk of bias 
and Drummond checklist scores. These results will be 
explored for high, moderate, low and very low-quality 
evidence. Systematic biases associated with the quality of 
evidence will be presented.
Amendments
Amendments to this protocol will be captured and docu-
mented with reference to saved searches and analysis 
methods, which will be recorded in bibliographic data-
bases (OVID), Endnote and Excel templates for data 
collection and synthesis. Deviations to this protocol will 
be documented in a research manuscript that will be 
submitted for peer-reviewed publication.
dIscussIon
In light of the findings in previous reviews of economic 
analyses in patient safety, this review is a timely update 
on a high-priority topic in healthcare. A strength of the 
proposed study is the application of transparent proce-
dures for searching health economic literature. These 
procedures are (1) application of the Neyt and Chalon-
procedure for economic literature searches in MEDLINE, 
which is a published procedure,16 (2) full publication of 
both MeSH and research-group derived search terms 
associated with each theme/facet, (3) use of a repro-
ducible deduplication procedure for Endnote article 
management software. Second, we aim to address two 
aspects—scope and quality—to determine how research 
in this area has matured since 2011. This is important 
because many health systems are facing efficiency and 
sustainability challenges, which require robust economic 
evidence to support decision-making in patient safety. 
This review aims to support targeted decision-making in 
the medical profession that is, synthesising the evidence 
by population, setting and disease area. The breadth of 
the search strategy should therefore improve the trans-
lational aspects of the anticipated research findings. A 
weakness of this study is the close, but imperfect repli-
cation of previous reviews. This limits the comparability 
of this study’s findings with others’, which also limits our 
interpretation of the maturation of evidence. In addition, 
considering previous findings, a large sample size for 
statistical pooling of effect size(s) within subgroups is not 
anticipated. This may limit the strength of this protocol as 
a means of producing a quantitative synthesis.
Acknowledgements The composition of the search terms and procedural aspects 
of the search strategy were significantly improved with support from Jacqueline 
Cousins, information specialist at the Imperial College London.
contributors AC conceptualised this research, designed and wrote the protocol. 
RM contributed to the conceptualisation and commented on multiple versions of 
the protocol. EMr contributed to the conceptualisation and commented on multiple 
versions of the protocol. JM contributed to the conceptualisation and commented 
on multiple versions of the protocol. EM leads the economics theme of the NIHR 
PSTRC at Imperial College and contributed to the conceptualisation of this work and 
commented on the penultimate draft. AD provides broader oversight of the NIHR 
PSTRC at Imperial College and contributed to the conceptualisation of this work and 
commented on the penultimate draft.
Funding This work is supported by the National Institute for Health Research 
(NIHR) Patient Safety Translation Research Centre. The views of the authors do not 
necessarily reflect those of the NHS, NIHR or the Department of Health.
competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEncEs
 1. Levinson DR. Office of the Inspector General. Adverse events 
in hospitals: national incidence among Medicare beneficiaries. 
Washington, DC: Department of Health and Human Services, 2010. 
https:// oig. hhs. gov/ oei/ reports/ OEI- 06- 09- 00090. pdf
 2. Vincent C, Neale G, Woloshynowych M. Adverse events in 
British hospitals: preliminary retrospective record review. BMJ 
2001;322:517–9.
 3. Frontier Economics. Exploring the costs of unsafe care in the NHS. 
London: Department of Health, 2014.
 4. Meltzer D. Economic analysis in patient safety: a neglected 
necessity. BMJ Qual Saf 2012;21:443–5.
 o
n
 18 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017089 on 18 August 2017. Downloaded from 
6 Carter AW, et al. BMJ Open 2017;7:e017089. doi:10.1136/bmjopen-2017-017089
Open Access 
 5. Etchells E, Koo M, Daneman N, et al. Comparative economic 
analyses of patient safety improvement strategies in acute care: a 
systematic review. BMJ Qual Saf 2012;21:448–56.
 6. de Rezende BA, Or Z, Com-Ruelle L, et al. Economic evaluation 
in patient safety: a literature review of methods. BMJ Qual Saf 
2012;21:457–65.
 7. A Review Group of the Cochrane Collaboration. Cochrane Effective 
Practice and Organization of Care Group: EPOC Resources for 
Review Authors. 2011.
 8. Drummond MF, Jefferson TO. Guidelines for authors and peer 
reviewers of economic submissions to the BMJ. the BMJ Economic 
evaluation Working Party. BMJ 1996;313:275–83.
 9. Karnon J, Campbell F, Czoski-Murray C. Model-based cost-
effectiveness analysis of interventions aimed at preventing 
medication error at hospital admission (medicines reconciliation). J 
Eval Clin Pract 2009;15:299–306.
 10. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and 
cost of recombinant human erythropoietin to avoid one transfusion-
related adverse event in critically ill patients. Crit Care Med 
2005;33:497–503.
 11. Maenthaisong R, Chaiyakunapruk N, Thamlikitkul V. Cost-
effectiveness analysis of chlorhexidine gluconate compared with 
povidone-iodine solution for catheter-site care in Siriraj Hospital, 
Thailand. J Med Assoc Thai 2006;89:S94–101.
 12. Waters HR, Korn R, Colantuoni E, et al. The business case for 
quality: economic analysis of the Michigan Keystone Patient Safety 
Program in ICUs. Am J Med Qual 2011;26:333–9.
 13. Regenbogen SE, Greenberg CC, Resch SC, et al. Prevention of 
retained surgical sponges: a decision-analytic model predicting 
relative cost-effectiveness. Surgery 2009;145:527–35.
 14. Wright J, Veale T, 2014. Retrospective evaluation of the impact of 
including HEED in literature searches for economic evaluations and 
economic models. InterTASC ISSG Workshop
 15. Vincent CA, Pincus T, Scurr JH. Patients' experience of surgical 
accidents. Qual Health Care 1993;2:77–82.
 16. Neyt M, Chalon PX. Search MEDLINE for economic evaluations: 
tips to translate an OVID strategy into a PubMed one. 
Pharmacoeconomics 2013;31:1087–90.
 o
n
 18 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017089 on 18 August 2017. Downloaded from 
